Buy the dip in biotechs - RBC [Seeking Alpha]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Seeking Alpha
HealthcareBuy the dip in biotechs - RBCSep. 21, 2020 3:34 PM ET|Gilead Sciences, Inc. (GILD)Douglas W. HouseIn a note RBC regards yesterday's selloff in biotechs as an "especially attractive entry point" for leading names such names as Gilead Sciences (-2.1%SRPT-1.8%CNST-5.0%Analysts, led by Brian Abrahams, believe GILD could head back toward the $80s citing its "increasingly cohesive" oncology strategy and potential upside on breast cancer antibody-drug conjugate Trodelvy (sacituzumab govitecan-hziy).RBC remains a "believer" in SRPT's DMD gene therapies, looking forward to microdystrophin data in Q1 2021.CNST does not reflect the "degree of de-risking" or long-term upside for lead BET inhibitor CPI-0610 which may improve upon Incyte's (INCY-2.2%GILD, SRPT and CNST are26%19%65%Click to subscribe to real-time analytics on GILDNow read:Incyte FDA Approvals To Propel Future Growth »
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights [Yahoo! Finance]Yahoo! Finance
- Autoimmune Hepatitis Diagnosis and Treatment Market Size to Reach USD 19.15 Bn by 2032 [Yahoo! Finance]Yahoo! Finance
- FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six [Yahoo! Finance]Yahoo! Finance
- FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as SixBusiness Wire
- Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 2/6/24 - Miss
GILD
Sec Filings
- 3/28/24 - Form ARS
- 3/28/24 - Form DEF
- 3/28/24 - Form DEFA14A
- GILD's page on the SEC website